Education
About Us
Working with TipRanks
Follow Us
Island Pharmaceuticals Ltd (AU:ILA)
:ILA
RESEARCH TOOLSreports
ILA Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.06 - AU$0.28
Previous CloseN/A
Volume208.69K
Average Volume (3M)582.76K
Market Cap
AU$33.80M
Enterprise ValueAU$5.72M
Total Cash (Recent Filing)AU$3.99M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Aug 21, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding233,093,030
10 Day Avg. Volume338,821
30 Day Avg. Volume582,762
Financial Highlights & Ratios
PEG Ratio-0.33
Price to Book (P/B)4.32
Price to Sales (P/S)0.00
P/FCF Ratio-2.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Island Pharmaceuticals Ltd News
PremiumCompany Announcements
Island Pharmaceuticals Announces Cessation of Securities
PremiumCompany Announcements
Island Pharmaceuticals Corrects Securities Announcement
PremiumCompany Announcements
Island Pharmaceuticals Appoints New Director, Strengthening Leadership
PremiumCompany Announcements
Island Pharmaceuticals Announces Cessation of Securities
PremiumCompany Announcements
Island Pharmaceuticals Announces Director Departure
PremiumCompany Announcements
Island Pharmaceuticals Appoints Jason Carroll as Non-Executive Chairman
PremiumCompany Announcements
Island Pharmaceuticals’ ISLA-101 Shows Promising Results in Dengue TrialOptions Prices
Currently, No data available
---
Ownership Overview
3.55% Insiders
―
Mutual Funds
― Other Institutional Investors
96.45% Public Companies and
Individual Investors
ILA FAQ
What was Island Pharmaceuticals Ltd’s price range in the past 12 months?
Island Pharmaceuticals Ltd lowest share price was AU$0.06 and its highest was AU$0.28 in the past 12 months.
What is Island Pharmaceuticals Ltd’s market cap?
Island Pharmaceuticals Ltd’s market cap is AU$33.80M.
When is Island Pharmaceuticals Ltd’s upcoming earnings report date?
Island Pharmaceuticals Ltd’s upcoming earnings report date is Aug 21, 2025 which is in 46 days.
How were Island Pharmaceuticals Ltd’s earnings last quarter?
Island Pharmaceuticals Ltd released its earnings results on Feb 27, 2025. The company reported -AU$0.011 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.011.
Is Island Pharmaceuticals Ltd overvalued?
According to Wall Street analysts Island Pharmaceuticals Ltd’s price is currently Overvalued.
Does Island Pharmaceuticals Ltd pay dividends?
Island Pharmaceuticals Ltd does not currently pay dividends.
What is Island Pharmaceuticals Ltd’s EPS estimate?
Island Pharmaceuticals Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Island Pharmaceuticals Ltd have?
Island Pharmaceuticals Ltd has 233,093,030 shares outstanding.
What happened to Island Pharmaceuticals Ltd’s price movement after its last earnings report?
Island Pharmaceuticals Ltd reported an EPS of -AU$0.011 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 14.286%.
Which hedge fund is a major shareholder of Island Pharmaceuticals Ltd?
Currently, no hedge funds are holding shares in AU:ILA
Island Pharmaceuticals Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:ILA Sentiment 70%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
101.38%
12-Months-Change
Fundamentals
Return on Equity
-143.22%
Trailing 12-Months
Asset Growth
144.04%
Trailing 12-Months
Company Description
Island Pharmaceuticals Ltd
Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. The company has a research collaboration agreement with Monash University to screen known molecules against host targets; research and development collaboration with Griffith University to screen for active anti-viral molecules in a rational repurposing strategy; and research collaboration agreement with Compounds Australia, a drug library containing approximately four and a half thousand molecules that could be searched for drug re-purposing and pipeline development. It also has a cooperative research and development agreement with the U.S. Army in preparation for its Phase II clinical study for ISLA-101; supply agreement with Catalent for manufacture of Fenretinide softgels for dengue fever trial participants; and right to reference National Cancer Institute IND for Isla101. The company was founded in 2017 and is based in Camberwell, Australia.
Technical Analysis
Actinogen Medical
―
Biotron
―
Immutep Ltd
―
Recce Pharmaceuticals Ltd.
―
Arovella Therapeutics Limited
―